Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Foresee Pharmaceuticals Co., Ltd.

http://www.foreseepharma.com/

Latest From Foresee Pharmaceuticals Co., Ltd.

Asia Deal Watch: Otsuka Gets Japanese Rights To Perception’s Mood Disorder Candidate

Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences

Deals Business Strategies

AstraZeneca/MSD’s Koselugo Among 14 New Hopefuls At EMA

New drugs from Eli Lilly, Pfizer, Janssen, GSK, Arvelle, BioCryst, Diurnal and Myovant are also among the latest products the European Medicines Agency is evaluating for potential pan-EU approval.

Europe Approvals

Last Year’s Winners Build On Successes

Firms that achieved recognition at last year’s Global Generics & Biosimilars Awards have continued to build on that success in the months since.

Generic Drugs Biosimilars

Value-Added Oncology Round-Up: Foresee Files In US For Leuprolide

Foresee is seeking a US commercial partner for the long-acting leuprolide it has just filed in the US; Sun has launched ready-to-infuse gemcitabine in the US as the first in an intended line of pre-mixed cancer therapies.

Value-Added Medicines Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Drug Delivery
      • Controlled Release
  • Biotechnology
    • Drug Discovery Tools
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • Foresee Pharmaceuticals Inc.
UsernamePublicRestriction

Register